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Abstract
Background: PTEN-induced kinase 1 (PINK1) is linked to recessive Parkinsonism (EOPD). Pink1 deletion results in impaired
dopamine (DA) release and decreased mitochondrial respiration in the striatum of mice. To reveal additional mechanisms of
Pink1-related dopaminergic dysfunction, we studied Ca
2+ vulnerability of purified brain mitochondria, DA levels and
metabolism and whether signaling pathways implicated in Parkinson’s disease (PD) display altered activity in the
nigrostriatal system of Pink1
2/2 mice.
Methods and Findings: Purified brain mitochondria of Pink1
2/2 mice showed impaired Ca
2+ storage capacity, resulting in
increased Ca
2+ induced mitochondrial permeability transition (mPT) that was rescued by cyclosporine A. A subpopulation of
neurons in the substantia nigra of Pink1
2/2 mice accumulated phospho-c-Jun, showing that Jun N-terminal kinase (JNK)
activity is increased. Pink1
2/2 mice 6 months and older displayed reduced DA levels associated with increased DA turnover.
Moreover, Pink1
2/2 mice had increased levels of IL-1b, IL-12 and IL-10 in the striatum after peripheral challenge with
lipopolysaccharide (LPS), and Pink1
2/2 embryonic fibroblasts showed decreased basal and inflammatory cytokine-induced
nuclear factor kappa-b (NF-kB) activity. Quantitative transcriptional profiling in the striatum revealed that Pink1
2/2 mice
differentially express genes that (i) are upregulated in animals with experimentally induced dopaminergic lesions, (ii)
regulate innate immune responses and/or apoptosis and (iii) promote axonal regeneration and sprouting.
Conclusions: Increased mitochondrial Ca
2+ sensitivity and JNK activity are early defects in Pink1
2/2 mice that precede
reduced DA levels and abnormal DA homeostasis and may contribute to neuronal dysfunction in familial PD. Differential
gene expression in the nigrostriatal system of Pink1
2/2 mice supports early dopaminergic dysfunction and shows that Pink1
deletion causes aberrant expression of genes that regulate innate immune responses. While some differentially expressed
genes may mitigate neurodegeneration, increased LPS-induced brain cytokine expression and impaired cytokine-induced
NF-kB activation may predispose neurons of Pink1
2/2 mice to inflammation and injury-induced cell death.
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Introduction
Mutations in the PARK6 gene encoding PINK1 are the second
most frequent cause for EOPD [1,2]. PINK1 is a ubiquitously
expressed serine/threonine kinase with a mitochondrial targeting
sequence that directs import of PINK1 into mitochondria [2,3,4].
In cultured cells, PINK1 protects against oxidative stress-induced
cytochrome c release and apoptosis through phosphorylation of
the mitochondrial chaperone TRAP1 [5]. Pink1-deficient Drosoph-
ila displayed mitochondrial degeneration associated with apoptotic
muscle degeneration and DA neuron loss, which could be rescued
by overexpression of Parkin [6,7,8,9]. Work in cultured mamma-
lian cells has shown that PINK1 directly phosphorylates Parkin
[10] and that PINK1 is required for recruitment of Parkin to
mitochondria with impaired membrane potential [11,12]. In turn,
Parkin promotes the degradation of functionally impaired
mitochondria through ubiquitination-dependent autophagy
[11,12,13]. Thus, PINK1 and Parkin cooperate in mitochondrial
quality control by selectively promoting the degradation of
dysfunctional mitochondria [14,15]. In contrast to the severe
mitochondrial defects and degenerative phenotypes of Pink1-
deficient flies, mice lacking Pink1 showed normal numbers and
morphology of mitochondria and failed to develop DA neuron loss
[16,17]. Instead, they manifested milder defects, including
impaired evoked DA release and mitochondrial respiration in
the striatum [16,17,18]. The reason for the different phenotypes in
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a greater capacity to compensate for Pink1 deficiency than flies.
Such compensatory changes may include enhanced autophagy
[19,20] or increased mitochondrial biogenesis [21]. Alternatively,
Pink1-defcient mice may compensate through changes in the
expression of genes that protect against the effects of Pink1 ablation
in vivo, possibly downstream of mitochondrial dysfunction. It has
also not been studied whether Pink1 deficiency affects the activity
of cell death pathways implicated in PD, such as the MAP kinase
pathway [22]. To further study the consequences of Pink1 gene
deletion in mice and its effects on gene expression in the
nigrostriatal system, we have generated and analyzed a new line
of Pink1-deficient mice. Here we demonstrate that mitochondria
from the brain of Pink1-deficient mice undergo Ca
2+-induced
permeability transition at a lower threshold and that pro-apoptotic
Jun N-terminal kinase (JNK) signaling is increased in the
substantia nigra of Pink1
2/2 mice. Importantly, DA levels are
reduced in Pink1
2/2 mice six months and older, which is
associated with increased DA turnover. We further show that
ablation of Pink1 results in reduced cytokine-induced NF-kB
activity in Pink1
2/2 embryonic fibroblasts and increased levels of
IL-1b, IL-10 and IL-12 in the striatum of Pink1
2/2 mice
challenged with a low dose of LPS. Quantitative transcriptional
profiling revealed that genes known to become activated after
dopaminergic lesions were upregulated in the striatum of two
month-old Pink1
2/2 mice, indicative of early dopaminergic
dysfunction. Interestingly, several genes that participate in axonal
regeneration and/or inhibit innate immune responses were
overexpressed, while certain pro-inflammatory and apoptotic
genes associated with neurodegeneration showed lower expression
in Pink1
2/2 mice. This suggests that Pink1
2/2 mice may mitigate
neurodegeneration by adapting the expression of a set of genes
towards increased neuroprotection. Taken together, our results
show that Pink1 ablation enhances the sensitivity to Ca
2+-induced
mitochondrial permeability transition, triggers pro-apoptotic JNK
signaling and causes a decline in striatal DA levels associated with
increased DA turnover. Transcriptional profiling data suggest that
Pink1 deletion may cause neuroinflammation and axonal damage,
which are compensated for by specific changes in gene expression.
While these changes may in part prevent neurodegeneration in
Pink1
2/2 mice, increased expression of cytokines in the striatum in
response to peripheral inflammation may cause enhanced
sensitivity to neuroinflammation, oxidative stress and brain injury.
Further characterization of the role of these mechanisms in
neuroprotection or neuronal loss will lead to better animal models
for recessive Parkinsonism, as well as the identification of pathways
that may be exploited as future targets for PD therapy.
Results
Generation and molecular characterization of Pink1-
deficient mice
Homologous recombination in mouse ES cells transfected with
the targeting vector (construction described in the Methods) led to
the replacement of Pink1 exons 4 and 5 with a phosphoglycerate
kinase (PGK) promoter-driven neomycin phosphotransferase (neo)
expression cassette and the deletion of essential portions of the
PINK1 kinase domain (Figure 1). About 2% of the G418-resistant
ES colonies harbored a heterozygous deletion of the Pink1 gene
(Fig. 1C). These gene-targeted clones were identified by PCR
screening with primers P1 and P2 (Fig. 1) and subsequently
confirmed by Southern blot analysis using probes homologous to
sequences 59 and 39 of the targeting vector (Fig. 2A). Internal
probes were used to rule out additional random insertions of the
targeting vector in the genome of the targeted clones (data not
shown). Injection of two gene-targeted ES cell clones yielded
highly chimeric mice that transmitted the Pink1 gene deletion to
their offspring. Genomic Southern blot analysis of tail DNA from
the F2 generation demonstrated the presence of all three
genotypes (Fig. 2B). Next, we verified that Pink1
2/2 mice lacked
functional Pink1 mRNA. First, expression of exon 4-containing
PINK1 transcripts was quantified by real-time reverse transcription
PCR with primers located in Pink1 exon 3 and exon 4, the latter of
which is deleted in the mutant Pink1 allele. Pink1 mRNA
expression was normalized to 18S rRNA levels in the same
samples. The ratio of Pink1 mRNA to 18S rRNA was 0.8260.12
for wildtype mice (n=3). A single Pink1
+/2 mouse showed a value
of 0.52 (63% of wildtype), while Pink1
2/2 mice yielded an average
signal of 060 (n=6). This shows that no exon 4-containing Pink1
transcripts were detected in Pink1
2/2 mice. Second, to analyze for
the possibility of alternatively spliced transcripts originating from
the mutated Pink1 allele, we carried out PCR with forward primers
located in exon 3 and reverse primers located in exon 6, 7 or 8.
These primer pairs are expected to generate PCR products of
specific lengths for the Pink1 wildtype allele, and correspondingly
shorter PCR products if alternatively spliced mutant Pink1
transcripts are present in cells (Fig. 3A). All expected bands for
full-length Pink1 transcripts were detected in wildtype and het-
erozygous mutant (Pink1
+/2) animals. In contrast, the Pink1
2/2
mice failed to produce the same bands (as expected) as well as any
bands indicative of alternative splicing (Fig. 3A). These results
show that alternative splicing (exon 4/5 skipping) does not occur in
Pink1
2/2 mice. Third, we carried out real-time PCR with primers
located in exon 1 and 3. As shown in Fig. 3B, the levels of
transcripts encompassing exons 1–3 in the brain of Pink1
2/2 mice
were reduced to 6.8% of wildtype. Using an N-terminal antibody
against PINK1 [23], we also examined whether a low amount (less
than 6.8%) of a truncated form of PINK1 might still be expressed
in Pink1
2/2 mice. We used total brain, heart and embryonic
fibroblast extracts from wildtype and Pink1
2/2 mice for Western
blot analysis. However, although the antibody was shown to detect
PINK1 in transfected cells [23], it was not sensitive enough to
reveal the much lower levels of endogenous PINK1, because no
specific bands of either 66 kDa (mitochondrial PINK1) or 55 kDa
(cytosolic PINK1) were observed in any of the wildtype tissues and
cells tested (data not shown). The lack of suitable antibodies to
detect endogenous Pink1 was also reported by others [17]. We
conclude that the targeted Pink1 gene deletion prevented the
generation of normal and aberrantly spliced Pink1 transcripts.
Furthermore, if Pink1
2/2 mice express an N-terminal portion of
PINK1 protein, its levels are very low (less than 6.8% of normal
amounts) and it lacks any kinase activity. Therefore, the mice
described in this work are functionally PINK1-deficient.
Brain mitochondria from Pink1-deficient mice display
reduced threshold for calcium-induced permeability
transition pore (PTP) opening
Recently, it has been shown that mitochondria of Pink1-deficient
neurons accumulate higher basal levels of Ca
2+ in the matrix (due
to reduced calcium efflux capacity) and display reduced mito-
chondrial Ca
2+ storage capacity associated with Ca
2+ overload
[24]. To study whether mitochondria from the brain of Pink1-
deficient mice show increased sensitivity to Ca
2+, we exposed
preparations of Ficoll-purified whole brain mitochondria from two
month-old Pink1-deficient mice and wildtype controls to increasing
concentrations of Ca
2+, and measured PTP opening using the
Ca
2+-sensitive fluorescent dye CaG5N and TMRE to monitor
changes in mitochondrial membrane potential (DYM) [25]. Pink1-
DA and Mitochondrial Defects in Pink1
2/2 Mice
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16038deficient brain mitochondria displayed a significant reduction in
Ca
2+ buffering capacity, which could be ameliorated by the
addition of the PTP inhibitor cyclosporine A (CsA) (Fig. 4A). As a
consequence mitochondria from Pink1
2/2 mice underwent
permeability transition (mPT) at significantly lower concentrations
of Ca
2+ compared to those of wildtype mice (Fig. 4B). Because
CaG5N is an indicator of the extra-mitochondrial calcium
concentration, the results cannot be attributed to differences in
the dye loading capacity between wildtype and Pink1
2/2
mitochondria. We also measured mitochondrial production of
reactive oxygen species (ROS) [25] but found no difference in
ROS production between mitochondria purified from Pink1-
deficient and wildtype brain (data not shown), consistent with
previous results [18].
Accumulation of phosphorylated c-Jun in the substantia
nigra of Pink1
2/2 mice
JNK is a member of the MAP kinase family and has been
implicated in neuronal cell death in a variety of circumstances
including PD pathogenesis [22]. JNK is activated by oxidative and
other types of stress and in turn phosphorylates c-Jun, its major
substrate. In Drosophila, Parkin negatively regulates JNK activity
[26]. To assess JNK activity in the nigrostriatal system of mice, we
stained wildtype and Pink1
2/2 brain sections containing the
substantia nigra with an antibody to phosphorylated c-Jun using
the nickel-enhanced DAB method. Interestingly, we found that
phospho-c-Jun accumulated in the substantia nigra of Pink1
2/2
but not wildtype mice (Fig. 5). At least a proportion of the
phospho-c-Jun signals are most likely within nuclei of dopaminer-
gic neurons, as they are surrounded by cytosol positive for tyrosine
hydroxylase (TH) (arrows in Fig. 5C–F). To verify that phospho-c-
Jun was expressed in dopaminergic neurons we carried out double
labeling of phospho-c-Jun and TH using fluorescent secondary
antibodies for analysis by confocal microcopy. However, phospho-
c-Jun was not detected by fluorescent immunohistochemistry,
suggesting that its expression was very weak (see Discussion).
Nonetheless, expression of phosphorylated c-Jun was specific for
Pink1-deficient mice, as all three Pink1 knockout mice showed
phospho-c-Jun expression while none of the wildtype mice did.
These results show that increased JNK activation occurs in the
substantia nigra of Pink1-deficient mice and may play a role in
Pink1-related Parkinsonism.
Decreased dopamine levels associated with increased
dopamine turnover in Pink1
2/2 mice aged six months
and older
To study whether the targeted Pink1 mutation affected
dopaminergic parameters, we measured the levels of DA in the
striatum by HPLC in mice between 2 and 12 months of age.
Pink1
2/2 mice aged 6 months and older had significantly lower
DA levels in the striatum than their wildtype controls (Fig. 6A).
However, stereological quantification of DA neuron numbers in 1-
year old Pink1
2/2 and wildtype mice showed no significant
difference, although the average number was 22% lower in
Pink1
2/2 mice (Fig. 6B). This suggested that dopaminergic
neurons of Pink1
2/2 mice synthesize less dopamine and/or that
Figure 1. Inactivation of the mouse Pink1 locus by gene targeting in ES cells. (A) Mouse Pink1 gene structure, (B) targeting vector and (C)
mutated Pink1 gene lacking exons 4 and 5 after homologous recombination with the targeting vector. The PINK1 kinase domain is encoded within
exons 2–8, with exons 4 and 5 specifying amino acids 257–374. Active site Asp362 and at least 15 familial PD-associated Pink1 mutations cluster in
exons 4 and 5 [143].
doi:10.1371/journal.pone.0016038.g001
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the first time, that DA turnover is increased in Pink1
2/2 mice at
those ages where DA levels are lower (Fig. 6C). These results
confirm that Pink1 deficiency can cause lower DA levels [17] and
further suggest that increased DA turnover may be involved in this
defect.
Loss of Pink1 activates expression of stress-inducible
transcription factor genes
To gain additional insights into mechanisms promoting
dopaminergic dysfunction in response to Pink1 ablation, we
compared striatal gene expression profiles between two month-
old wildtype and Pink1
2/2 mice. We focused on cAMP/Ca
2+-
regulated genes and genes of the Akt/protein kinase B (Akt/PKB)
and nuclear factor kappa-b (NF-kB) pathways, because abnor-
malities in these pathways have been implicated in PD [27,28,29].
We found that several of the upregulated genes encoded stress-
inducible transcription factors of the ATF and AP1 families,
including activating transcription factor 3 (ATF-3), c-fos, FosB,
JunB and Egr-2 (Table 1). ATF3 is induced by multiple signals,
including inflammatory cytokines, DNA-damaging agents and
physiological stresses [30,31]. Interestingly, increased striatal
expression of Fos-related antigens and JunB has been observed
following neuronal injury and degeneration in the DA system
[32,33]. Moreover, striatal c-fos expression is regulated by DA
[34] and, in the DA-depleted striatum, may be induced via
compensatory super-sensitivity of DA receptors [35,36]. Likewise,
expression of Egr-2 is regulated in a D1 and D2 DA receptor-
dependent fashion [37,38].
Ablation of PINK1 increases expression of Cyr61 and
Amphiregulin
We also found significantly increased expression of Cyr61 and
Amphiregulin in the striatum of Pink1-deficient mice (Table 1).
Cyr61 is an immediate early gene induced downstream of JNK
activation that has been linked to neurodegeneration [39]. Cyr61
transcription is negatively regulated by the forkhead transcription
factor FOXO3a [40], which has been shown to activate the Pink1
gene under conditions of growth factor deprivation [41].
Amphiregulin is a mitogen for adult neural stem cells [42] and
acts as an autocrine survival factor for sensory neurons where it
promotes axonal outgrowth [43].
Altered expression of genes that regulate innate
immunity and MAP kinase signaling in the striatum of
Pink1-deficient mice
Pink1
2/2 mice displayed altered expression of many genes that
regulate innate immune responses and the MAPK pathway
(Table 1). For example, the inhibitor-a of NF-kB( I kB-a), MAPK
phosphatase-1 (MKP-1/Dusp-1) and the receptor for tumor
necrosis factor-related apoptosis inducing ligand (TRAIL-R2) were
all upregulated in Pink1
2/2 striatum. IkB-a provides a negative
feedbackregulationforNF-kBsignaling[44,45].MKP-1inactivates
Figure 2. Southern blot analysis of ES cell colonies and F2 generation mice. (A) Genomic DNA from PCR-positive ES cell clones was double-
digested with NcoI/SacI or NdeI/XbaI and hybridized with the indicated probes. The location of the two probes and expected sizes of the various DNA
fragments for wildtype (WT) and Pink1
+/2 ES cells are shown in Figure 1. (B) Tail DNA from offspring of Pink1
+/2 breeder pairs was digested with NcoI
and SacI and analyzed by Southern blot using ‘‘outside exon 8’’ probe. The 4513 bp band indicates the wildtype Pink1 allele and the 4152 bp band is
diagnostic for the mutated Pink1 allele. Location of the probe and restriction enzyme cleavage sites are shown in Figure 1.
doi:10.1371/journal.pone.0016038.g002
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regulation [46] and functions as an important negative regulator of
innate and adaptive immune responses [46,47,48]. TRAIL-R2 is
induced by a variety of stress factors and its activation involves both
NF-kB and p53 dependent pathways [49,50]. Four genes were
expressed at lower levels in the striatum of Pink1
2/2 mice (Table 1).
These were p300/CREB-binding protein associated factor (p300/
CBP-associated factor, PCAF), tumor necrosis factor receptor-1a
(TNF-R1), tumor necrosis factor receptor-1b (TNF-R2), and
glycogen synthase kinase-3 beta (GSK-3b). The histone acetyltrans-
ferase PCAF functions as a transcriptional co-activator of a subset of
NF-kB regulated genes [51], including cyclooxygenase-2 (COX-2)
[52]. However, PCAF is also required for post-activation shut-off of
NF-kB gene transcription through acetylation of p65 [53]. TNF
receptors mediate numerous functions in cells that range from
inflammation, apoptosis and cell survival [54,55,56]. TNF-R
engagement activates NF-kB signaling and the MAPK pathway
and thus often results in tissue inflammation [56]. GSK-3b has been
linked to neurodegeneration and the neuropathology of PD
[57,58,59,60]. Taken together, these results show that several key
regulators and effectors of the TNF-R, NF-kB and MAPK signaling
pathways are abnormally expressed in the striatum of Pink1-
deficient mice.
Basal and inflammatory cytokine-induced NF-kB activity
is reduced in PINK1-deficient mouse embryonic
fibroblasts (MEF)
The transcriptional profiling results indicated abnormalities in
TNF-R and NF-kB signalingin the striatum of Pink1-deficientmice.
The inflammatory cytokines tumor necrosis factor-a (TNF-a)a n d
interleukin 1b (IL-1b) are potent inducers of NF-kB signaling
[61,62]. In addition bacterial LPS activates the NF-kB pathway via
Toll-like receptor 4 (TLR-4) and TNF-a expression. To study basal
and inflammatory cytokine-induced NF-kB activity, we transfected
primary MEF from Pink1-deficient and wildtype mice with an NF-
kB-luciferase reporter plasmid and measured luciferase activity
Figure 3. Analysis and quantification of Pink1 mRNA expression. Total RNA isolated from the brain of mice was converted to cDNA. (A) PCR
with a forward primer located in exon 3 and reverse primers located in exon 6, 7 or 8, generating expected PCR products of 480, 624 and 1001 bp for
the Pink1 wildtype allele in wildtype and Pink1
+/2 samples. In contrast, PCR products of 133, 149 and 289 that would arise if exon 3 were directly
spliced to exon 6, 7, or 8 in transcripts derived from the mutant Pink1 allele were absent in both Pink1
+/2 and Pink1
2/2 samples. This shows that
alternatively spliced transcripts are not generated from the disrupted Pink1 allele. (B) Quantitative real-time PCR with primers located in exon 1
(forward) and exon 3 (reverse) showing that Pink1
2/2 mice express at most 6.8% of a truncated Pink1 mRNA encompassing exons 1–3, compared to
wildtype mice. However, such a truncated mRNA would not give rise to any PINK1 protein with kinase activity (see main text).
doi:10.1371/journal.pone.0016038.g003
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Compared to wildtype MEF, fibroblasts derived from Pink1
2/2
mice showed significantly reduced NF-kB activity in both the basal
state and after treatment with inflammatory cytokines (Fig. 7A).
Likewise, LPS-induced NF-kB activity was decreased in Pink1
2/2
MEF (Fig. 7A). EGFP expression in control wells of wildtype and
Pink1
2/2 MEF (Fig. 7B) was used to confirm comparable
transfection efficiency. These results show that lack of Pink1 impairs
NF-kB activity and reduces inflammatory signal-dependent NF-kB
pathway induction.
Pink1
2/2 mice show increased striatal levels of IL-1b, IL-
12 and IL-10 after treatment with LPS
Given the increased expression of anti-inflammatory genes in
the striatum and enhanced JNK activity in the substantia nigra of
Pink1
2/2 mice, we were interested to test whether Pink1
2/2 mice
showed abnormal expression of inflammatory and/or anti-
inflammatory cytokines in the striatum. The relative striatal levels
of twelve cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12,
IL-17a, TNF-a, G-CSF, GM-CSF) were measured using an
enzyme-linked immunosorbent assay (ELISA). We did not find a
significant difference in the expression of these cytokines between
wildtype and Pink1
2/2 mice (data not shown). However, after
peripheral challenge with a low dose of LPS, Pink1
2/2 mice
expressed higher levels of IL-1b, IL-12 and IL-10 in the striatum
compared to wildtype mice (Fig. 8A). In addition, a tendency for
increased expression of IL-2 (p=0.053), IL-4 (p=0.085) and
TNF-a (p=0.072) was observed. In the brain, microglia cells are
the major source for LPS-induced cytokine production [63].
Therefore we studied cytokine production of cultured neonatal
microglia in response to LPS. The levels of IL-10 were significantly
Figure 4. Pink1
2/2 brain mitochondria have significantly lower Ca
2+ load capacity. Brain mitochondria were isolated from 2 month-old
male wildtype (WT) and Pink1
2/2 (PINK1-KO) mice to measure calcium load capacity. Mitochondrial protein (200 mg) from each genotype was
incubated in a 2-ml reaction mixture containing 125 mM KCl buffer (37uC) along with fluorescence indicators: 100 nM Calcium Green 5-N (for
measurement of extra-mitochondrial calcium concentration; excitation 506 nm, emission 532 nm) and 100 nM TMRE (for measurement of membrane
potential; excitation 550 nm, emission 575 nm). Mitochondrial bioenergetic coupling was assessed by following changes in membrane potential
(TMRE fluorescence, data not shown) following the addition of pyruvate + malate (PM), ADP (A) and oligomycin (O) at 1, 2 and 3 min respectively.
Calcium infusion began at 5 min (rate of 160 nmol/mg protein/min) and changes in extra-mitochondrial Ca
2+ were assessed (CaG5N fluorescence). In
Panel A, representative traces are shown to depict the calcium uptake and storage capacity before the opening of the mitochondrial permeability
transition (mPT) pore. Mitochondria from PINK1-KO mice had decreased calcium load capacity, indicated by the earlier onset of mPT (sharp rise in
extra-mitochondrial Ca
2+) as compared to WT mice. Calcium load capacity in PINK-KO mice was increased by incubating mitochondria with
cyclosporine A (CSA, 1 mM), a specific inhibitor of the PTP, showing that the reduced calcium load capacity was due to enhanced mPT. In Panel B,
quantitative measurements of maximal calcium load capacity before mPT for mitochondria isolated from WT and PINK1-KO mice are shown and
expressed as nmol Ca
2+ infused/mg protein. The graph in panel B illustrates a significant loss of calcium load capacity in PINK1-KO mice (*P,0.05,
n=4 mice per genotype).
doi:10.1371/journal.pone.0016038.g004
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2/2 but not wildtype microglia,
suggesting that IL-10 secretion is potentiated in Pink1
2/2
microglia (Fig. 8B). This is in agreement with increased IL-10
levels in the striatum of Pink1
2/2 mice (Fig. 8A). However, IL-1b
levels did not significantly increase in cultured microglia from
either genotype (Fig. 8B) and IL-12 levels were too low to be
detected with the ELISA (data not shown). In contrast, the
expression of IL-6, TNF-a and G-CSF was dramatically induced
after LPS in both genotypes, showing that the microglia cells were
competent to respond to an inflammatory stimulus (Fig. 8C). As T
cells can also synthesize cytokines, we quantified the expression of
the T cell marker CD3 in the striatum by real-time PCR. T cells
are not normally present in significant numbers in the brain.
Consistent with this the expression of CD3 in the striatum of
normal mice was very low, as evidenced by Ct values in the range
of 39 (Fig. 8D). In addition, CD3 expression did not increase after
LPS treatment. Thus, we believe that T cells are likely not
involved in augmenting brain cytokine levels in LPS-treated
Pink1
2/2 mice. This is consistent with a role for T cells in antigen-
specific adaptive immune responses, which take longer to develop
than eight hours between LPS injection and cytokine analysis in
our experiment. Taken together, these results show that Pink1
2/2
mice display abnormal brain cytokine expression in response to
peripheral LPS injection and suggest that Pink1
2/2 mice may be
more susceptible to inflammation-induced DA neuron death
[64,65,66,67,68].
Discussion
Ca
2+-induced mitochondrial permeability transition is
increased in the absence of Pink1
It has been shown that striatal mitochondria from Pink1
2/2
mice show impaired state 3 respiratory activities of complex I and
II and that Pink1
2/2 cortical mitochondria are more sensitive to
H2O2-induced defects, while the levels of anti-oxidant enzymes
were normal [18]. Here, we show for the first time that isolated
purified mitochondria from the brain of Pink1
2/2 mice display an
enhanced vulnerability to Ca
2+-induced mPT. Whereas cultured
neurons of Pink1
2/2 mice were reported to be more sensitive to
Ca
2+-induced cell death due to Ca
2+ overload [24], mitochondria
Figure 5. Accumulation of phospho-c-Jun in the substantia nigra of Pink1
2/2 mice. Cryosections of the substantia nigra from wildtype (A–
B) and Pink1
2/2 mice (C–F) were stained with antibodies against phospho-c-Jun (nickel-DAB staining) and subsequently TH (fluorescent) as described
in the Methods. Arrows in panels C–F point to cells expressing nuclear phospho-c-Jun that is surrounded by TH-positive cytosol, suggesting that
these cells are dopaminergic neurons. AP coordinates of sections according to the mouse stereotaxic atlas (Franklin and Paxinos, The Mouse Brain in
Stereotaxic Coordinates, Third Edition 2007) are indicated to demonstrate that phospho-c-Jun was expressed in distantly spaced sections of Pink1
2/2
mice (C–F), including sections anatomically matched to wildtype control mice (compare A–B and C–D). All three Pink1
2/2 mice but none of the
wildtype mice showed expression of phospho-c-Jun in a subpopulation of TH-positive neurons.
doi:10.1371/journal.pone.0016038.g005
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Ca
2+ than mitochondria from wildtype mice [18]. This led to the
conclusion that, independent of Ca
2+ and the mitochondrial PTP,
Pink1
2/2 mitochondria are more sensitive to stress [18].
However, in these experiments the swelling assay was used and
only one concentration of Ca
2+ was tested. Additionally, a
differential effect of Ca
2+ loading could have been missed due to
low coupling of the mitochondrial preparations used in these
experiments (RCR,5). In contrast, we incubated highly coupled
mitochondria (RCR.10) with increasing concentrations of Ca
2+,
and measured mitochondrial Ca
2+ uptake and the sudden Ca
2+
release and loss of DYM at the time of PTP opening using the
Ca
2+-sensitive dye CaG5N and TMRE to monitor DYM [25].
Our results show that freshly isolated brain mitochondria lacking
Pink1 undergo mPT at lower Ca
2+ concentrations than
mitochondria from wildtype mice. Thus, it is likely that the
facilitated Ca
2+-induced mPT in Pink1-deficient mitochondria
renders neurons in the brain more vulnerable to Ca
2+-mediated
death. Interestingly, we observed enhanced Ca
2+-induced mito-
chondrial PTP opening with whole brain mitochondria, showing
that this defect is not specific for the dopaminergic system.
Because Ca
2+ plays an important role in the physiology of all
neurons, this raises the question of how Pink1 mutations in
humans lead to the selective loss of DA neurons. An unusual
aspect of adult dopaminergic neurons is that they express unique
L-type Ca
2+ channels required for rhythmic pace-making and
tonic DA release, and blocking Ca
2+ influx through these
channels has been shown to protect against toxin-induced
dopaminergic system degeneration in animal models of PD
[69,70]. Therefore, the life-long reliance on L-type Ca
2+ channels
may render DA neurons particularly vulnerable to perturbations
in mitochondrial Ca
2+ buffering capacity. This hypothesis can be
tested in future experiments with neurons derived from Pink1-
deficient mice.
Increased JNK activity in the substantia nigra of Pink1
2/2
mice
We found that phosphorylated c-Jun accumulates in the
substantia nigra of Pink1
2/2 mice. Nuclear phospho-c-Jun was
clearly surrounded by TH-positive cytosol in at least a proportion
of the cells, suggesting that phospho-c-Jun is expressed in
dopaminergic neurons. To further investigate this, we attempted
colocalization of TH and phospho-c-Jun by confocal microscopy.
However, phospho-c-Jun was not detectable with fluorescent
secondary antibodies, while the highly sensitive nickel-enhanced
DAB staining method was able to reveal phospho-c-Jun
expression. We have observed that detection of at least one
other protein, c-fos, is significantly more sensitive with the nickel-
DAB method compared to fluorescent immunohistochemistry.
Similar c-fos signals were obtained with a 50-fold higher dilution
of the primary antibody (1:15000) by the nickel-DAB method
when compared to fluorescent detection (1:300) (data not shown).
As phospho-c-Jun was detected with 1:300-diluted primary
antibody only with the nickel-DAB method, we conclude that
its expression is very weak. In the absence of confocal
colocalization we cannot conclude with certainty that phospho-
c-Jun is expressed within dopaminergic neurons of Pink1
2/2
mice, although we believe this to be likely based on the data
presented in Figure 5. We have not studied whether the phospho-
c-Jun positive neurons express other markers such as neurogenin
[18] and dopamine and cAMP-regulated phosphoproteins
(DARPP-32), a regulator of DA-induced signal transduction
[71]. Increased JNK signaling has been shown to promote
dopaminergic neuron death [22,72]. Phospho-c-Jun has been
detected in cytosolic granules adjacent to Lewy bodies in neurons
in PD and dementia with Lewy bodies [73]. Moreover, genetic
deletion of specific JNK isoforms prevented complex I inhibitor
(MPTP)-mediated [74] and axotomy-induced [75] cell death of
nigral dopaminergic neurons in animal models of PD. These
results suggest that JNK may be activated downstream of
mitochondrial and possibly axonal damage in Pink1
2/2 mice.
In Drosophila, parkin deletion resulted in the activation of JNK in
a small subgroup of dopaminergic neurons that underwent
degeneration, suggesting that parkin negatively regulates JNK
signaling [26]. Because PINK1 kinase activity is required for
many Parkin functions and Parkin acts downstream of PINK1
[11,14,76], increased JNK signaling in Pink1
2/2 mice may in
part be due to reduced Parkin activity. Taken together, these data
implicate Pink1 in the inhibition of JNK signaling and the
mitigation of the effects of pro-apoptotic MAP kinase signaling.
Figure 6. Dopamine levels, dopamine turnover and dopamine
neuron counts. (A) Decreased DA levels in the striatum of Pink1
2/2
mice aged 6 months and older. (B) Normal counts of dopaminergic
neurons in the substantia nigra pars compacta (SNc) of 1-year old
Pink1
2/2 mice. (C) Increased DA turnover in Pink1
2/2 mice. Eight mice
per genotype were used for catecholamine analysis (A and C). Five
wildtype and six Pink1
2/2 mice were used to determine nigral DA
neuron numbers by unbiased stereology (B). * P,0.05, ** P,0.01,
*** P,0.001.
doi:10.1371/journal.pone.0016038.g006
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of Pink1
2/2 mice
Importantly, we show that Pink1
2/2 mice aged 6 months and
older have significantly lower DA levels in the striatum than their
wildtype controls. This is in contrast to another group that found
DA levels to be normal in 8–9 month-old Pink1
2/2 mice [16].
However, reduced DA levels were found in Pink1
2/2 mice of
independent origin at 9 and 22–24 months of age, although the
dopaminergic neuron counts in the SNc were normal [17]. Our
data are in agreement with the latter results. However, the
Pink1
2/2 mice described here show a significant decline in DA
levels at a much earlier age than previously reported [17].
Furthermore, we show for the first time that DA turnover is
increased in Pink1
2/2 mice, providing a potential mechanism for
the decline in DA in the absence of (significant) neuronal loss. It is
well established that PD is characterized by increased DA
turnover which occurs early in the disease [77]. Increased DA
turnover is associated with elevated oxidative stress [78], which
may exarcerbate dopaminergic dysfunction in the long-term.
Thus, our studies suggest that abnormal DA homeostasis may
precede and contribute to neuronal loss in Pink1-related
Parkinsonism.
Transcriptional changes in the striatum of young Pink1
2/2
mice indicate early dopaminergic dysfunction preceding
dopamine loss
Quantitative striatal gene expression analyses showed that the
genes displaying altered expression in Pink1
2/2 mice could be
grouped into three categories. The first and largest category
contained genes that regulate innate immune responses and/or
apoptosis. Within this category, MKP-1, ATF3 and TRAIL-R2
were upregulated in Pink1
2/2 mice. MKP-1 attenuates JNK-
dependent apoptosis [46] and is upregulated specifically in healthy
but not degenerating neurons after axotomy, demonstrating that it
participates in a neuronal stress response promoting survival [79].
MKP-1 also acts as a negative regulator of innate immune
responses by suppressing the expression of pro-inflammatory
cytokines, endotoxic shock and activation of both p38 MAPK and
JNK [80,81,82]. Likewise, ATF3 and TRAIL-R2 are stress-
inducible genes that reduce innate immune responses and tissue
Table 1. Genes with significantly altered expression in the striatum of Pink1
2/2 mice.
Gene Description Threshold Cycles Expression relative to HKG Expression P N
Ct WT Ct Pink1
2/2
2
2(AVG DCt)
WT
2
2(AVG DCt)
Pink1
2/2 Pink1
2/2/WT
Upregulated Genes
Fos FBJ osteosarcoma
oncogene
29.2961.40 27.3661.62 1.81610
22 5.06610
22 2.80 0.031 5
Tnfrsf10b TRAIL receptor 2 34.4160.56 33.560.25 3.74610
24 6.46610
24 1.72 0.048 4
Nfkbia NF-kB inhibitor-a 27.7160.54 26.7660.30 4.35610
22 6.60610
22 1.52 0.0002 5
Fosb FBJ osteosarcoma
oncogene B
30.7361.31 28.6260.97 2.65610
23 8.24610
23 3.12 0.019 4
Cyr61 Cysteine-rich protein 61 30.1560.40 28.1761.10 3.97610
23 1.12610
22 2.83 0.018 4
JunB JunB oncogene 32.4661.23 30.560.56 7.99610
24 2.24610
23 2.80 0.005 4
Egr2 Early growth response 2 28.5161.17 26.661.06 1.24610
22 3.34610
22 2.68 0.049 4
Atf3 Activating transcription
factor3
33.260.30 31.6960.91 4.78610
24 9.82610
24 2.05 0.027 4
Dusp1 Map kinase
phosphatase-1
26.660.28 25.1260.61 4.64610
22 9.34610
22 2.01 0.0005 4
Areg Amphiregulin 34.160.62 32.7660.75 2.56610
24 4.68610
24 1.83 0.027 4
Down-regulated Genes
Tnfrsf1b TNF receptor 2 31.4160.47 32.2160.73 3.0610
23 1.58610
23 0.53 0.01 4
Tnfrsf1a TNF receptor 1 32.0160.56 32.4960.63 1.97610
23 1.30610
23 0.65 0.022 4
Pcaf p300/CBP-associated
factor
26.5660.52 27.0160.37 8.72610
22 5.76610
22 0.65 0.035 4
Gsk3b Glycogen synthase
kinase-3b
25.3860.71 25.6760.76 2.55610
21 1.70610
21 0.66 0.01 4
Gene expression was analyzed using NF-kB, PI3 kinase/Akt and cAMP/Ca
2+ signaling PCR Arrays (SA Biosciences) as described in the Methods. Ct values (mean 6 SD) for
individual genes are indicated for wildtype (WT) and Pink1
2/2 mice. In addition, expression of each gene relative to the housekeeping genes (HKG) is indicated for WT
and Pink1
2/2 mice and was used to calculate the fold change in gene expression (Pink1
2/2/WT). All PCR arrays contain five HKG (b-glucuronidase, hypoxanthine
guanine phosphoribosyl transferase, heat shock protein 90-alpha, glyceraldehyde-3-phosphate dehydrogenase, and b-actin), to which the expression of the genes of
interests is normalized. None of the HKG was differentially expressed between WT and Pink1
2/2 mice. Data were evaluated and calculated with the DDCt method using
the RT
2 Profiler PCR Array Data Analysis software and resources available online (http://sabiosciences.com/pcr/arrayanalysis.php). The p values were calculated based on
a Student’s t-test of the replicate 2
2(AVG DCt) values for each gene in the WT and Pink1
2/2 groups. All genes with a p,0.05 that were upregulated or down-regulated by
at least a factor of 1.5 are shown. N is the number of data points available for a given gene for both genotypes after running five arrays (five mice per genotype were
analyzed). Occasionally, a well (gene) yielded no signal at all for reasons that are unrelated to actual lack of expression. For example, if a specific gene became
detectable at PCR cycle number 25 in four mice but showed no expression in the fifth mouse of the same genotype, we concluded that this must be an experimental/
technical error rather than actual lack of expression and omitted the corresponding data. However, we still used five data points for the other genotype if available. For
a description of the function of the listed genes in innate immunity, MAPK signaling and/or their involvement and regulation in PD and models of PD, see the main text
and references therein.
doi:10.1371/journal.pone.0016038.t001
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inhibit Toll-like receptor signaling [83,84,85,86]. In contrast, the
expression of GSK-3b and both TNF receptors, which mediate
pro-inflammatory signals, was suppressed in Pink1
2/2 mice.
Deficiency of TNF receptors inhibits microglial activation [87]
and protects mice partially against MPTP-induced loss of
dopaminergic terminals and DA decline [67]. The role of GSK-
3b in innate immunity is complex and its effect on NF-kB function
appears to depend on the cell type studied [88,89,90]. Reduced
GSK-3b expression may be a protective adaptation to increased
JNK signaling in Pink1
2/2 mice, because GSK-3b inhibition has
been shown to block pro-apoptotic JNK [91]. On the other hand,
GSK-3b also functions as a negative regulator of pro-inflamma-
tory cytokine expression [92,93] and decreased GSK-3b expres-
sion may render Pink1
2/2 mice more vulnerable to TNF-a, IL-1b
and LPS-induced brain inflammation [88,91,94]. However, it
remains to be seen whether decreased GSK-3b expression is asso-
ciated with altered GSK-3b activity in the striatum of Pink1
2/2
mice. Overall, the genes identified in category 1 suggest that
ablation of Pink1 results in increased brain inflammation and MAP
kinase pathway activation, possibly through heightened oxidative
stress [95,96,97,98]. In response, Pink1
2/2 mice appear to adapt
the expression levels of critical genes controlling innate immune
responses, perhaps to mitigate inflammation and inflammation-
induced neuronal damage (see also below).
Category 2 contained immediate-early transcription factors,
including c-fos, FosB and Egr2, which were among the most highly
overexpressed in the striatum of Pink1
2/2 mice (Table 1). The
same genes were upregulated in the striatum of animals with toxin
or surgery-induced dopaminergic deficits, or chronic alterations of
dopaminergic neurotransmission, which depended on D1 and D2
DA receptor signaling [35,99,100]. In addition, c-fos, FosB and
Egr-2 were all upregulated by methamphetamine, which can cause
long-lasting neurodegenerative effects that are at least in part due
to activation of D1 DA receptors [37]. Collectively, these results
suggest increased DA receptor signaling in the striatum of Pink1-
deficient mice, possibly as compensation to reduced DA
neurotransmission. Consistent with this, reduced KCl-evoked
DA release was described in acute striatal slices from 2–3
month-old Pink1
2/2 mice previously [16]. Our results indicate
that, in addition to evoked DA release, tonic DA release may also
be affected in Pink1
2/2 mice, leading to lasting elevations in
postsynaptic striatal expression of immediate early genes. In
addition Cyr61 was upregulated in Pink1
2/2 mice. Cyr61 is an
immediate-early gene induced downstream of JNK activation that
has been implicated in neurodegeneration [39].
Several genes of category 3 are induced in response to axonal
injury and have been shown to promote axonal outgrowth and
sprouting. In particular, overexpression of JunB and amphiregulin
in the striatum of Pink1
2/2 mice may be neuroprotective. JunB
transgenic mice displayed significantly increased long-term
survival of substantia nigra dopaminergic neurons after axotomy
[101]. Amphiregulin is a mitogen for adult neural stem cells [42]
and has been shown to promote axonal outgrowth [43]. Several
groups described that ATF3 stimulates axonal outgrowth and
sprouting after neuronal injury [102,103,104,105]. Overexpres-
sion of ATF3 protected hippocampal neurons against excitotoxic
cell death [106] and PC12 cells against mutant huntingtin-induced
toxicity [107]. However, ATF3 has also been shown to promote
cell death by mediating the apoptotic effects of p38 MAPK [31],
and its expression preceded the death of spinal motor neurons and
correlated with phosphorylation of c-Jun in a mouse model of
familial amyotrophic laterals sclerosis [108]. Furthermore, it has
been proposed that, in the nigrostriatal system, ATF3 and
phospho-c-Jun participate in axotomy-induced neurodegeneration
[109]. However, another study showed that ATF3 inhibits JNK-
mediated neuron death through induction of Hsp27 expression
and Akt activation [110]. Thus, an alternative interpretation is
that ATF3 may be induced in response to increased JNK signaling
to protect against neuron death. Overall, the changes in the
expression of category 3 genes suggest the presence of axonal
dysfunction and increased pro-apoptotic signaling in Pink1
2/2
mice. This in turn may activate regenerative programs, including
axonal sprouting and outgrowth, or activation and recruitment of
neuronal stem cells that depend on JunB and amphiregulin.
Altered cytokine expression in the striatum of Pink1
2/2
mice after peripheral inflammation
As discussed above, upregulation of genes that antagonize
innate immune responses suggests that compensatory gene
expression may prevent neuroinflammation in Pink1-deficient
Figure 7. Basal and inflammatory signal-induced NF-kB activity
is reduced in Pink1
2/2 embryonic fibroblasts. Wildtype and
Pink1
2/2 MEF were transfected with plasmid pNF-kB-luc (Clontech).
Twenty-four hours after transfection the cells were incubated for
8 hours with 30 ng/ml TNF-a, 10 ng/ml IL-1b, 100 ng/ml LPS or
remained untreated (control) and luciferase activity was measured as
described in the Methods. (A) NF-kB-dependent luciferase activity,
expressed as relative light units (RLU) per mg protein. Data represent
pooled values from two independent experiments with similar results.
In each experiment luciferase activity was measured in five wells per
condition. Non-transfected cells (NT) showed no luciferase activity. (B)
Wildtype and Pink1
2/2 fibroblasts were transfected with the same
plasmid/lipofectamine mixture to ensure equal transfection efficiency,
which was confirmed to be the case with an EGFP expression plasmid
as described in the Methods. ** P,0.01.
doi:10.1371/journal.pone.0016038.g007
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of twelve cytokines measured by ELISA in the striatum were
comparable between Pink1
2/2 and wildtype mice. However, after
peripheral LPS treatment Pink1
2/2 mice expressed higher levels of
striatal IL-1b, IL-10 and IL-12 than wildtype controls. Although
not quite statistically significant, the levels of IL-2, IL-4 and TNF-
a also tended to be higher in Pink1
2/2 mice. Interestingly, IL-1b,
TNF-a, IL-2 and IL-4 levels were shown to be elevated in the
brain and cerebrospinal fluid in juvenile Parkinsonism and PD
[111,112,113]. The same cytokines were also elevated in the
serum of patients with idiopathic PD [114,115]. While higher
levels of IL-10 may be protective in PD [115,116,117], the
pro-inflammatory cytokines IL-1b and TNF-a have been
shown to promote and exarcerbate DA neuron death
[64,65,66,68,118,119]. Additionally, IL-12 may be involved in
PD pathogenesis [115]. Unlike wildtype microglia, cultured
microglia isolated from neonatal Pink1
2/2 mice responded with
a significant increase in IL-10 secretion after LPS stimulation, in
agreement with elevated levels of IL-10 in Pink1
2/2 striatum.
Unexpectedly, IL-1b secretion was not potentiated in microglia
from either genotype and IL-12 expression was too low to be
measured reliably. Nonetheless, the fact that other cytokines,
including IL-6, TNF-a and G-CSF were highly induced by the
LPS treatment showed that cultured microglia were competent to
respond to an inflammatory stimulus. However, the results also
suggest that in vitro cultured neonatal microglia may not fully
mirror the capacity and cytokine profile of adult brain microglia
when stimulated with LPS. Although T cells can also synthesize
cytokines, we favor the idea that microglial cells are responsible for
the increased cytokine expression in the brain, as brain microglial
cells strongly respond to LPS via Toll-like receptor activation [63].
In fact, significant up-regulation of various cytokine mRNAs in the
striatum was shown to occur as shortly as four hours after
peripheral injection of a LPS dose comparable to that used in our
studies [120]. In contrast, T cells are present in very low numbers
in the brain and part of the antigen-specific adaptive immune
response, which takes longer to develop than the short time
between LPS injection and cytokine analysis in our experiments
(eight hours). Real-time PCR analysis of CD3 expression
confirmed that this T cell marker is barely detectable in the
striatum and its levels also did not increase after LPS injection.
Among the brain resident cells, astrocytes are also known to
Figure 8. Cytokine expression in the striatum and isolated microglial cultures. (A) Wildtype and Pink1
2/2 mice (n=4 mice/genotype) were
injected ip with 0.33 mg LPS/g body weight. Cytokines in striatal homogenates (corresponding to 100 mg total protein) were measured eight hours
later by ELISA as described in the Materials and Methods. * P,0.05, compared to wildtype mice. Basal cytokine levels, measured in a separate
experiment, were not statistically different between wildtype and Pink1
2/2 mice. (B) Microglial cultures derived from the forebrain of neonatal
wildtype and Pink1
2/2 mice were incubated with 100 ng/ml LPS for 24 hours in 24-well plates and the cytokines were measured with an ELISA as
described in the Methods (n=8 wells per condition). (C) Strong induction of IL-6, TNF-a and G-CSF in wildtype and Pink1
2/2 microglia cells
demonstrates that the cells were capable of responding to the LPS stimulus. In panels B and C, background-corrected absorbance is plotted (OD450
minus OD570). (D) Real-time PCR expression analysis of CD3 mRNA (specific T cell marker) in the striatum of control and LPS-treated wildtype and
Pink1
2/2 mice, showing that the T cell marker is barely detectable (Ct values of 39.67 and 38.46) and not increased by LPS treatment.
doi:10.1371/journal.pone.0016038.g008
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[121]. Our experiments have not addressed a possible role of
astrocytes in cytokine production. Future studies with microglia
and mixed astrocytes/microglia cultures from the adult brain are
needed to determine whether microglia can fully recapitulate the
altered cytokine profile observed in the brain after LPS injection,
or whether astrocytes may be involved as well. Because peripheral
LPS increased the expression of both pro-inflammatory (IL-1b and
IL-12) and anti-inflammatory (IL-10) cytokines in Pink1
2/2 mice,
the net effect on neuronal survival is difficult to predict. However,
as Pink1 defects cause PD in humans, a plausible and testable
hypothesis is that abnormal cytokine regulation in the brain of
Pink1
2/2 mice enhances the vulnerability to inflammation-
induced DA neuron death. Interestingly, Parkin-deficient mice
treated for 3–6 months with repeated, low doses of systemic LPS
developed subtle fine-motor deficits and DA neuron loss that were
more pronounced than in wildtype controls [122], indicating that
enhanced neuronal vulnerability to inflammation may play a role
in recessive Parkinsonism.
Impaired basal and inflammatory cytokine-induced NF-
kB signaling in Pink1
2/2 embryonic fibroblasts
The transcription factor NF-kB has many roles in the regulation
of cell survival, apoptosis and innate immunity [63]. NF-kBi sa
key regulator of inflammatory gene expression in microglial cells,
which can cause brain inflammation when excessively activated
[63]. However, NF-kB is also an important survival factor for
neurons and often induces genes favoring survival [123]. For
example, NF-kB is required for TNF-a induced expression of the
neuroprotective genes Bcl-2 and Bcl-x in primary hippocampal
neurons [124] and protects neurons against glucose deprivation,
calcium-induced cell death and oxidative stress [125,126]. Our
results show that, compared to wildtype MEF, basal and TNF-a
induced NF-kB activity is reduced in fibroblasts derived from
Pink1
2/2 mice. Moreover, we found that NF-kB activation in
response to IL-1b and LPS is also impaired in Pink1
2/2 MEF.
Taken together, these results show a deficit of Pink1
2/2 embryonic
fibroblasts in NF-kB signaling induced by cytokines, and suggest
that Pink1 deficiency may predispose neurons to inflammation and
oxidative stress-induced apoptosis in vivo. Consistent with this, it
has recently been shown that Pink1 enhances NF-kB activation by
phosphorylation of Parkin [127]. It should be noted that one
group reported that selective inhibition of NF-kB activation
reduced MPTP-induced dopaminergic degeneration in the
sporadic mouse model of PD [128]. However, another group
concluded that NF-kB plays no role in MPTP-induced DA neuron
loss [129]. Further studies with Pink1
2/2 mice will reveal whether
abnormal NF-kB signaling renders these mice more or less
susceptible to exogenous stress-induced DA neuron loss.
Conclusions
In conclusion, our results show that ablation of Pink1 generates a
valuable preclinical model of PD in mice, showing some of the
cardinal features of PD including reduced levels of DA and
increased DA turnover. These defects are preceded by early
transcriptional changes indicative of dopaminergic neuron dys-
function, which may be caused by alterations in mitochondrial
Ca
2+ buffering capacity as well as increased JNK signaling in the
substantia nigra. In addition, lack of Pink1 reduces basal and
cytokine-induced NF-kB signaling and increases the levels of both
pro-inflammatory and anti-inflammatory cytokines after periph-
eral LPS challenge. This may lead to decreased neuroprotection
against a variety of stresses [123,126,130,131,132], impaired
repair after brain injury [133,134], reduced response to neuro-
trophic factors [135] and/or increased vulnerability to inflamma-
tion-induced DA neuron loss due to an imbalance between pro-
inflammatory and anti-inflammatory mediators [64,65,66,67,68].
The differential gene expression profile observed in the striatum of
Pink1-deficient mice is compatible with neuroprotective adapta-
tions to increased MAP kinase signaling and inflammation in the
Pink1
2/2 brain. Experiments aimed to eliminate or over-express
selected genes that are altered in Pink1
2/2 mice will ultimately
lead to improved animal models for recessive Parkinsonism and
the identification of genes and pathways that could serve as targets
for future PD therapy.
Materials and Methods
All animal work has been conducted according to national and
international guidelines and has been approved by the Animal
Care and Use Committee of the University of Kentucky with
identification number 2009-0453. The current approval is valid
until 3/9/2011.
Generation of Pink1
2/2 mice
A DNA fragment corresponding to nucleotides 3086-12111 of
the mouse Pink1 locus (Genbank accession NC_000070.5) was
amplified by PCR from mouse genomic DNA using a high-fidelity
DNA polymerase. The PCR product was subcloned into the
vector pGEM-T Easy (Promega) and the entire insert was
sequenced and its sequence was found to be identical with the
published Genbank entry. Subsequently, a 2011 bp internal
fragment spanning Pink1 nucleotides 7579 (intron 3) to 9590
(intron 5) was excised, removing Pink1 exons 4 and 5. This
fragment was replaced with a PGK-neo-pA cassette amplified by
PCR from plasmid ploxPFLPneo (Dr. James Shayman, University
of Michigan Medical School). 10
7 AB2.2 mouse ES cells (129/Sv)
were electroporated with 30 mg linearized targeting vector and
plated in ES-DMEM/15% ES-qualified FCS at 122610
6 cells
into 10-cm plates containing mitomycin C-inactivated primary
mouse embryonic fibroblasts. G418-resistant ES cell colonies were
picked individually at day 10 of selection (0.4 mg/ml G418) and
clones with a targeted Pink1 gene were identified by PCR with
primer P1 (59-attgctgaagagcttggcggcgaatgggct-39) located in the
neo gene and primer P2 (59-tgc tgactgctgcaagagccaggcgatca-39)
located in Pink1 exon 8 adjacent to the 39 end of the targeting
vector (shown in Figure 1). After confirmation of correct targeting
vector insertion at both 59 and 39 junctions and ruling out
additional random insertions by Southern blot analyses, ES cells
from two different clones were injected into C57BL/6 blastocysts.
Both clones yielded highly chimeric offspring that were crossed to
129/Sv;C57BL/6 F1 hybrid mice to generate F1 heterozygous
mutant mice. The latter were then intercrossed to obtain
homozygous mutant and wildtype mice for experiments.
Southern blots and Pink1 transcript analysis in mice
10–20 mg genomic DNA from the tails of mice was digested
with the indicated restriction enzymes and analyzed by Southern
blot using a-P
32-dCTP labeled random-primed DNA probes
(Stratagene Prime-It II kit). Total brain RNA was isolated with the
RiboPure kit (Ambion) and converted to cDNA with the
Superscript III kit (Invitrogen). Quantitative real-time PCR (Q-
PCR) for exon 4-containing transcripts was done with primers 59-
gcgaagccatcttaagcaaa-39 (exon 3 forward) and 59-agtagtgtggggg-
cagcata-39 (exon 4 reverse). Q-PCR for transcripts encompassing
exons 1-3 was done with primers 59-atccagaggcagttcatggt-39 (exon
1 forward) and 59-ttaagatggcttcgctggag-39 (exon 3 reverse). Pink1
transcript levels were normalized to 18S rRNA levels detected in
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done with forward primers located in exon 3 (59-ggctggagagtatg-
gagcag-39 and 59-agcgaagccatcttaagc aa-39) and reverse primers
located in exon 6 (59-ccaccacgctctacactgg-39), exon 7 (59-
caggtatcggct ttgctgta-39) and exon 8 (59-ccaggttagccagaaacagc-39).
Quantitative gene expression analysis with PCR arrays
Total RNA was isolated from the striatum of mice with the
RiboPure kit (Ambion). RNA quality was analyzed on RNA 6000
NanoLab Chips in the Agilent Bioanalyzer 2000 (Agilent
Technologies) of the University of Kentucky Microarray Facility.
Only RNAs with an RNA integrity number of at least 9 (on a scale
of 0–10) were used for analysis. One mg total RNA was converted
to cDNA using the RT
2 first strand synthesis kit (SA Biosciences,
MD) and the cDNA reaction was brought to a final volume of
111 ml with H2O. 102 ml diluted cDNA reaction was mixed with
2x RT
2 qPCR Master Mix (SA Biosciences) and H2O to reach a
final volume of 2.7 ml. 25 ml of the mixture was added into each of
the wells of the RT
2 Profiler PCR Arrays (SA Biosciences) and
PCR was carried out on the Roche480 Cycler using a cycling
program optimized for PCR arrays (SA Biosciences). Each PCR
array contained 84 transcripts of the corresponding signaling
pathway, a set of five housekeeping genes as internal controls and
additional controls for efficiency of reverse transcription, PCR and
the absence of contaminating genomic DNA. Data were analyzed
with the DDCt method using the PCR Array Data Analysis Web
Portal (SA Biosciences), which includes quality control for each
PCR run/array.
Measurement of mitochondrial Ca
2+ load capacity and
permeability transition
Mitochondria were isolated from whole brains of 8-week old
male wildtype or Pink1
2/2 mice as described previously [136].
Briefly, brains were homogenized in 2 ml ice-cold isolation buffer
(215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES,
1 mM EGTA, pH 7.2). Homogenates were centrifuged twice at
1,300 g for 3 min and then at 13,000 g for 10 min at 4uC, using
the supernatants and filling up to a final volume of 2 ml with
isolation buffer after each centrifugation. The final pellet was
resuspended in 0.5 ml isolation buffer and the cells were disrupted
in a nitrogen cell disruption bomb (model 4639, Parr Instruments,
IL) at 1200 psi for 10 min at 4uC. The resultant crude
mitochondrial fraction was placed onto a discontinuous Ficoll
gradient (2 ml 7.5% Ficoll solution layered on top of 2 ml 10%
Ficoll solution) and centrifuged at 100,000 g for 30 min at 4uC.
The resulting mitochondrial pellet was carefully separated,
resuspended and washed with isolation buffer (without EGTA).
After another centrifugation for 10 min at 10,000 g, the pellet was
resuspended in isolation buffer (without EGTA) and stored on ice
until analysis. This method yielded highly coupled mitochondria
with RCR of 14.562.1 and 12.561.9 for wildtype and Pink1
2/2
mice (n=7 preparations). Mitochondrial protein content was
measured with the BCA protein assay kit (Pierce, IL). Purified
mitochondria (100 mg protein/ml) were placed in constantly
stirred, temperature-controlled (37uC) cuvettes in 2 ml respiration
buffer (125 mM KCl, 0.1% BSA, 20 mM HEPES, 2 mM MgCl2
and 2.5 mM KH2PO4, pH 7.2), which contained 100 nM calcium
green-5N hexapotassium salt (CaG5N) (Molecular Probes,
ex506 nm, em532 nm) and 100 nM tetramethylrhodamine
(TMRE) (Molecular Probes, ex550 nm, em575 nm) to monitor
extra-mitochondrial calcium content and changes in mitochon-
drial membrane potential (DYM), respectively. Because CaG5N is
an indicator of the extra-mitochondrial calcium concentration and
not imported into mitochondria, data are not confounded by
possible differences in the dye loading capacity between wildtype
and Pink1
2/2 mitochondria. Scans began with a baseline reading
followed by addition of mitochondrial substrates (5 mM pyruvate
and 2.5 mM malate) at 1 min, 150 mM ADP at 2 min and 1 mM
oligomycin at 3 min. At 5 min, calcium chloride (32 mM) was
infused gradually through an infusion pump (model 310, KD
Scientific, MA) at a rate of 160 nmol per mg protein per minute
until the mitochondria were no longer able to sequester calcium,
as indicated by a rapid rise in CaG5N signal and loss of DYM. The
chemical uncoupler carbonyl cyanide 4-(trifluoromethoxy)phenyl-
hydrazone (FCCP) was added as a positive control at the end of
each run. In some experiments the PTP inhibitor CsA (1 mM) was
added at the start of the experiment and was shown to increase
Ca
2+ loading capacity. The maximum calcium storage capacity of
each mitochondrial preparation was quantified as previously
described [25].
NF-kB activity assay in mouse embryonic fibroblasts
Mouse embryonic fibroblasts (MEF) were prepared from
wildtype and Pink1
2/2 embryos at 15.5–16.5 dpc as described
(Nagy et al., 2003: Manipulating the Mouse Embryo, 3
rd edition,
CSHL Press). Cells were grown in DMEM, 10% fetal bovine
serum (FBS) supplemented with penicillin/streptomycin, 0.2 mM
L-glutamine and 0.1 mM 2-mercaptoethanol (all from Invitrogen)
in a 37uC incubator with 5% CO2. For experiments, cells were
plated in 24-well plates at 50,000 cells per well and transfected the
next day in fresh medium with 800 ng pNF-kB-luc plasmid
(Clontech) mixed with 1.6 ml lipofectamine LTX and PLUS
reagent prepared in OPTI-MEM (all from Invitrogen). Compa-
rable transfection efficiencies were confirmed with pEGFP-N1
plasmid (Clontech). For each condition wildtype and Pink1
2/2
cells were transfected with the same DNA/lipofectamine mixture.
24 hours after transfection, medium was changed and cells were
stimulated with 10 ng/ml IL-1b, 30 ng/ml TNF-a (R&D Systems,
MN) or 100 ng/ml LPS from Salmonella minnesota (Sigma, MO).
Eight hours after stimulation cells were lysed in cell culture lysis
buffer and luciferase activity measured with the luciferase reporter
assay system (Promega, WI). Luminescence was measured in a
luminometer (TD-20/20, Turner Design, Promega) and normal-
ized to total protein present in each sample (determined with BCA
kit). Comparable transfection efficiency was confirmed by
quantification of EGFP-positive cells in several wells of wildtype
and Pink1
2/2 MEF transfected in parallel in the same experi-
ments, using images taken with an Axiovert 40 fluorescence
microscope (Carl Zeiss, Germany) and analyzed with AxioVision
software version 4.8 (Carl Zeiss, Germany).
Expression of phospho-c-Jun and TH in the substantia
nigra
Brains from eight-week old wildtype and Pink1
2/2 mice were
fixed in 4% paraformaldehyde for 48 hrs at 4uC followed by slow
immersion in 30% (w/v) sucrose in PBS for 4 days. Thirty mm-
thick sections were prepared with a sliding freezing microtome
(Microm, Germany) and stored in cryopreservation solution (30%
(w/v) sucrose, 1% (w/v) polyvinylpyrrolidone, 30% ethylene
glycol, 100 mM sodium phosphate buffer, pH 7.2). Sections
containing the substantia nigra were washed in Tris-buffered
saline (TBS) and blocked in 5% donkey serum, 0.2% BSA, 0.3%
Triton X-100, 0.01% sodium azide in TBS for one hour at room
temperature (RT). Sections were incubated overnight at RT with
1:300 diluted phospho-c-Jun antibody (Cell Signaling, MA) in 2%
donkey serum, 0.2% BSA, 0.15% Triton X-100, 0.01% sodium
azide. After three washes in TBS the sections were incubated for
1 hour at RT with 1:500-diluted biotin-SP-conjugated donkey
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0.2% BSA in TBS. After washing as above sections were incubated
in freshly prepared, filtered nickel-diaminobenzidine (nickel-DAB)
solution (1.5g nickel ammonium sulfate, 25 mg DAB in 400 ml of
0.1 M sodium acetate buffer). Prior to use 2 ml of 30% hydrogen
peroxide was added to the nickel-DAB solution. Color develop-
ment in the sections (placed on a shaker) was monitored and the
reaction was stopped before background developed in control
sections incubated with secondary antibody only. Subsequently,
the same sections were used to identify TH-expressing neurons by
fluorescent IHC. For this purpose sections were washed in TBS,
re-blocked for 20 min in blocking buffer and incubated overnight
at 4uC with 1:1500 diluted sheep anti-TH antibody (Pel-Freeze,
AR). 1:500 diluted DyLight549-conjugated anti-sheep IgG
(Invitrogen) was used for 1 hour at RT as the secondary antibody.
After extensive washing in TBS, sections were mounted with
Permount (Fisher Scientific, NJ) and images captured through
phase-contrast (phospho-c-Jun) or fluorescent filters (TH) using an
Axiovert 40 microscope equipped with an AxioCam MRc5 digital
camera and AxioVision software (Carl-Zeiss, Germany).
Measurement of cytokines in the striatum and medium
of isolated cultured microglia cells
Six month-old mice were left untreated or given intra-peritoneal
(i.p.) injections of 0.33 mg LPS from Salmonella minnesota per gram
body weight. Eight hours after injection mice were euthanized and
brains harvested. Dose of LPS and time of analysis were chosen
based on a previous publication [120]. The striatum was dissected
from each brain on ice and homogenized with T-PER tissue
protein extraction reagent (Pierce Biotechnology, IL) containing
protease inhibitor cocktail (Sigma, MO) (20 ml buffer/mg tissue).
Homogenates were centrifuged (10,000 g, 5 min, 4uC) and
supernatants collected and stored at 280uC until analysis.
Cytokines in the striatal lysates (100 mg total protein) were
measured using Multi-Analyte ELISArray plates (SA Biosciences,
MD) according to the manufacturer’s instructions. The plates
allow for the simultaneous relative quantification of IL-1a, IL-1b,
IL-2, IL-4, IL-6, IL-10, IL-12, IL-17a, interferon-c, TNF-a,G -
CSF and GM-CSF. Primary microglia cultures were prepared
from the cerebral cortices of neonatal (1 day-old) wildtype and
Pink1
2/2 mice as previously described for rats [137]. Briefly,
forebrains were cleared from meninges, minced and gently
dissociated by repeated pipetting in PBS followed by filtration
through a 70-mm cell strainer (Falcon). Cells were collected by
centrifugation (1000 rpm, 10 min), resuspended in DMEM
containing 10% fetal calf serum and antibiotics (40 U/ml
penicillin and 40 mg/ml streptomycin), and cultured on 10-cm
cell culture dishes (1.3610
5 cells/cm
2)i n5 %C O 2 at 37uC.
Floating microglia, collected by shaking cultures at 90 rpm for
5 min, were harvested every week (between 2–7 weeks) and re-
seeded into wells of a 24-well plate to give pure microglial cultures.
For experiments, cultures were washed to remove non-adherent
cells and fresh medium was added. Cells (n=8 wells/condition)
were treated with 100 ng/ml LPS (Sigma) or left untreated for
24 h. Supernatants were collected, clarified by centrifugation and
used to quantify cytokines as described above.
Quantification of striatal catecholamines and nigral
dopaminergic neurons
Striatal tissue was dissected on an-ice-cold plate, tissue pieces
weighed and snap-frozen in liquid nitrogen. Samples were
homogenized in 300 ml of ice-cold 0.1 M perchloric acid
containing the internal standard dihydroxybenzylamine and
centrifuged for 5 min at 15,0006 g. Supernatants were filtered
through a 0.22 mm pore size membrane and diluted with HPLC
mobile phase prior to injection onto the HPLC column. Striatal
tissue levels of DA, 3, 4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) were measured by reverse phase HPLC
coupled to electrochemical detection as described [138]. TH-
positive neurons in 30 mm-thick sections of the substantia nigra
were stained with a sheep anti-TH antibody (Pel-Freeze) and
detected with biotinylated secondary antibody and the DAB
method as described by us previously [139,140]. The optical
fractionator [141,142] and dissector method for unbiased
stereological cell counting was used to estimate the numbers of
dopaminergic neurons using the Stereologer System and software
(Stereology Research Center, www.disector.com). Five wildtype
and six Pink1
2/2 mice were analyzed and neurons in every fourth
section of the SNc were counted (12 sections per mouse, both
hemispheres).
Data analysis and statistics
Data were analyzed using the Student’s t-test. Results are
expressed as mean 6 standard deviation. PCR Array data were
analyzed using the DDCt method and the web tools of SA
Biosciences(http://www.sabiosciences.com/pcr/arrayanalysis.php).
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